BIIB Biogen Inc.

Biogen to Present at the 35th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the 35th Annual J.P. Morgan Healthcare Conference. The webcast will be live on Monday, January 9, 2017 at 4:30 p.m. PST, 7:30 p.m. EST. To access the live webcast, please visit Biogen’s Investors section at www.biogen.com/investors. An archived version of the webcast will be available following the presentation.

About Biogen

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For more information, please visit www.biogen.com. Follow us on Twitter.

EN
20/12/2016

Underlying

BIIBBiogen Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Biogen Inc.

Laura Chico ... (+2)
  • Laura Chico
  • Thomas Yip
XENE XENON PHARMACEUTICALS INC
NBIX NEUROCRINE BIOSCIENCES INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
STOK STOKE THERAPEUTICS
EWTX EDGEWISE THERAPEUTICS INC
12/26/25 December 26, 2025 1 EN
 PRESS RELEASE
Free
BIIB BIOGEN INC.

The Journal of the American Medical Association (JAMA) Neurology Publi...

The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS Long-term data published in JAMA Neurology further illustrate the effects of Biogen’s QALSODY on function, strength, and survival in SOD1-ALSOver 3 years, a subset of QALSODY-treated participants regained previously lost function and strength, something not previously reported in the natural history of SOD1-ALSBiogen is committed to advancing additional ALS research, including the ongoing QALSODY ATLAS study in pre-symptom...

December 22, 2025 1 EN
Laura Chico ... (+2)
  • Laura Chico
  • Thomas Yip
XENE XENON PHARMACEUTICALS INC
NBIX NEUROCRINE BIOSCIENCES INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
STOK STOKE THERAPEUTICS
EWTX EDGEWISE THERAPEUTICS INC
12/19/25 December 19, 2025 1 EN
Wedbush Research
  • Wedbush Research
XENE XENON PHARMACEUTICALS INC
NBIX NEUROCRINE BIOSCIENCES INC.
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
ARDX ARDELYX INC
WVE WAVE LIFE SCIENCES
FMCC FEDERAL HOME LOAN MORTGAGE CORPORATION
STOK STOKE THERAPEUTICS
EWTX EDGEWISE THERAPEUTICS INC
NATL NCR ATLEOS CORPORATION
DBD DIEBOLD NIXDORF INCORPORATED
12/12/25 December 12, 2025 1 EN
Laura Chico ... (+2)
  • Laura Chico
  • Thomas Yip
XENE XENON PHARMACEUTICALS INC
NBIX NEUROCRINE BIOSCIENCES INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
STOK STOKE THERAPEUTICS
EWTX EDGEWISE THERAPEUTICS INC
12/12/25 December 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch